{"id":54772,"date":"2023-09-20T10:03:47","date_gmt":"2023-09-20T10:03:47","guid":{"rendered":"https:\/\/medsname.com\/vomistop\/"},"modified":"2026-04-30T10:24:53","modified_gmt":"2026-04-30T10:24:53","slug":"vomistop","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/vomistop\/","title":{"rendered":"Vomistop"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Vomistop?<\/h3>\n

Vomistop<\/strong> obsahuje domperidon 10 mg<\/strong>, perifern\u00ed antagonista dopaminov\u00e9ho receptoru D2, kter\u00fd urychluje vyprazd\u0148ov\u00e1n\u00ed \u017ealudku a zpev\u0148uje doln\u00ed j\u00edcnov\u00fd sv\u011bra\u010d. Je u\u017eite\u010dn\u00fd p\u0159i nevolnosti a zvracen\u00ed zp\u016fsoben\u00e9m opo\u017ed\u011bn\u00fdm vyprazd\u0148ov\u00e1n\u00edm \u017ealudku, regurgitac\u00ed, gastroparezou a funk\u010dn\u00ed dyspepsi\u00ed<\/strong>. Na rozd\u00edl od metoklopramidu domperidon v\u00fdrazn\u011b nepronik\u00e1 hematoencefalickou bari\u00e9rou \u2014 sedace, extrapyramidov\u00e9 reakce a tardivn\u00ed dyskineze jsou vz\u00e1cn\u00e9. V\u00fdroba Torrent Pharma v souladu s normami WHO-GMP. EMA omezuje pou\u017eit\u00ed na kr\u00e1tk\u00e9 k\u00fary (max. 7 dn\u00ed, 30 mg\/den) kv\u016fli m\u00edrn\u00e9mu riziku prodlou\u017een\u00ed QT intervalu.<\/p>\n<\/div>\n

Pro\u010d objedn\u00e1vat z MedsBase:<\/strong> \u2714 v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong> \u2714 Diskr\u00e9tn\u00ed balen\u00ed \u2714 Celosv\u011btov\u00e1 doprava \u2714 Ov\u011b\u0159en\u00e9 recenze z\u00e1kazn\u00edk\u016f (1 400+ z\u00e1kazn\u00edk\u016f)<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

\u26a0\ufe0f EMA omezen\u00ed domperidonu kv\u016fli riziku prodlou\u017een\u00ed QT intervalu \u2014 pouze kr\u00e1tk\u00e9 k\u00fary.<\/strong> Po p\u0159ezkoum\u00e1n\u00ed v roce 2014 je domperidon v Evrop\u011b omezen na zm\u00edrn\u011bn\u00ed p\u0159\u00edznak\u016f nevolnosti\/zvracen\u00ed v nejni\u017e\u0161\u00ed \u00fa\u010dinn\u00e9 d\u00e1vce po nejkrat\u0161\u00ed dobu (obvykle \u2264 7 dn\u00ed, max. 30 mg\/den u dosp\u011bl\u00fdch). Vyhn\u011bte se pou\u017eit\u00ed u osob nad 60 let, pokud p\u0159\u00ednosy nep\u0159ev\u00e1\u017e\u00ed rizika, u zn\u00e1m\u00e9ho prodlou\u017een\u00ed QT intervalu, poruchy elektrolyt\u016f (n\u00edzk\u00e9 K+\/Mg++), t\u011b\u017ek\u00e9ho po\u0161kozen\u00ed jater nebo p\u0159i sou\u010dasn\u00e9m u\u017e\u00edv\u00e1n\u00ed l\u00e9k\u016f prodlu\u017euj\u00edc\u00edch QT interval (azithromycin, citalopram, methadon) nebo siln\u00fdch inhibitor\u016f CYP3A4 (klarithromycin, ketokonazol, ritonavir). P\u0159i dlouhodob\u00e9m u\u017e\u00edv\u00e1n\u00ed m\u016f\u017ee doj\u00edt k hyperprolaktin\u00e9mii (galaktorea, gynekomastie, menstrua\u010dn\u00ed poruchy). Vyhn\u011bte se u Parkinsonovy choroby<\/strong> \u2014 antagonismus D2 zhor\u0161uje motorick\u00e9 p\u0159\u00edznaky; pokud je pot\u0159ebn\u00e1 perifern\u00ed blok\u00e1da D2 (nap\u0159. nevolnost vyvolan\u00e1 levodopou), m\u016f\u017ee b\u00fdt u\u017eite\u010dn\u00e1 v n\u00edzk\u00e9 d\u00e1vce pod odborn\u00fdm dohledem.<\/div>\n

Domperidon vs metoklopramid \u2014 praktick\u00fd rozd\u00edl<\/h2>\n

Oba jsou antagonist\u00e9 D2, ale pr\u016fnik do centr\u00e1ln\u00edho nervov\u00e9ho syst\u00e9mu je z\u00e1sadn\u011b odli\u0161n\u00fd.<\/p>\n\n\n\n\n\n\n\n\n\n\n
Vlastnost<\/th>\nDomperidon<\/th>\nMetoklopramid<\/th>\n<\/tr>\n<\/thead>\n
Pr\u016fnik hematoencefalickou bari\u00e9rou<\/td>\nMinim\u00e1ln\u00ed (perifern\u00ed)<\/td>\nV\u00fdznamn\u00fd (centr\u00e1ln\u00ed)<\/td>\n<\/tr>\n
EPS \/ dystonie<\/td>\nVz\u00e1cn\u00e9<\/td>\n\u010cast\u00e9 u mlad\u00fdch dosp\u011bl\u00fdch<\/td>\n<\/tr>\n
Tardivn\u00ed dyskineze (dlouhodob\u00e1)<\/td>\nVz\u00e1cn\u00e9<\/td>\nFDA black-box (omezen\u00ed na 5 dn\u00ed FDA \/ 12 t\u00fddn\u016f EMA)<\/td>\n<\/tr>\n
QT interval<\/td>\nMal\u00e9, ale re\u00e1ln\u00e9 (omezen\u00ed EMA 30 mg\/den, 7 dn\u00ed)<\/td>\nMinim\u00e1ln\u00ed p\u0159i standardn\u00edch d\u00e1vk\u00e1ch<\/td>\n<\/tr>\n
Pou\u017eit\u00ed u Parkinsonovy choroby<\/td>\nN\u00edzk\u00e1 d\u00e1vka pro nevolnost vyvolanou levodopou<\/td>\nVynechat (zhor\u0161uje motoriku)<\/td>\n<\/tr>\n
Antiemetick\u00e1 \u00fa\u010dinnost<\/td>\nSt\u0159edn\u00ed<\/td>\nSt\u0159edn\u011b siln\u00fd a\u017e siln\u00fd<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Vomistop je dod\u00e1v\u00e1n z v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong>. Ka\u017ed\u00e1 objedn\u00e1vka je diskr\u00e9tn\u011b zas\u00edl\u00e1na po cel\u00e9m sv\u011bt\u011b a je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a> \u2014 pokud nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me zdarma. Domperidon je antiemetikum volby pro nevolnost zp\u016fsobenou gastrickou st\u00e1zou a regurgitac\u00ed, zejm\u00e9na u pacient\u016f, u kter\u00fdch jsou obavy z extrapyramidov\u00fdch reakc\u00ed vyvolan\u00fdch metoklopramidem.<\/p>\n

Mechanismus \u00fa\u010dinku<\/h2>\n

Domperidon je deriv\u00e1t benzimidazolu, kter\u00fd selektivn\u011b blokuje perifern\u00ed D2 dopaminov\u00e9 receptory<\/strong>. Z toho vypl\u00fdvaj\u00ed dva klinicky v\u00fdznamn\u00e9 \u00fa\u010dinky:<\/p>\n